The FDA has appointed hematologist-oncologist Vinay Prasad, MD, to lead the agency’s Center for Biologics Evaluation and Research, according to a May 6 NBC News report.  As the head of CBER, Dr.

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

The Aurora system’s 40mm detector is stated to provide double the coverage of other hybrid systems' CT detectors.

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning ...

Complaint letters should only be sent in extreme circumstances. Keep in mind that a principal has a very tough job, their time is valuable, and you do not want to get the reputation as a helicopter ...

“Most people don’t want to credit samples [in that way],” says Rob Sevier, co-founder of Numero Group, which gets about three sample requests a week. To prevail in clearance ...

For the remaining 7 cases, deemed extension letters were issued with the condition of producing statutory forest, environment etc. clearance letters, submitting a non-payment letter and adhering ...

Based on this clearance, ALX Oncology will initiate a single-agent dose-escalation and expansion Phase 1 clinical trial for ALX2004 in mid-2025. “Clinical advancement of our first ADC and the first ...

Based on this clearance, ALX Oncology will initiate a single-agent dose-escalation and expansion Phase 1 clinical trial for ALX2004 in mid-2025. “Clinical advancement of our first ADC and the ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...